CYPHERPUNK TECHNOLOGIES INC. quarterly report, Q2 FY2020

Business context and reporting period

Filing identity warning: The request identifies CYPHERPUNK TECHNOLOGIES INC., but the supplied Form 10-Q is for Leap Therapeutics, Inc. (Nasdaq: LPTX). This summary reflects the filing text, which reports the quarter and six months ended June 30, 2020.

Leap is a clinical-stage biopharmaceutical company developing cancer therapies. Its lead candidate is DKN-01; the company had deprioritized TRX518 development in November 2019. DKN-01 and TRX518 were investigational and not FDA-approved.

Financial performance and position

Amounts below are in U.S. dollars; financial statement amounts are in thousands unless noted.

• Q2 revenue came from recognizing part of BeiGene’s $3.0 million upfront payment. The company reported no product sales or royalty revenue.
• Q2 net loss included a $943 foreign-currency gain, versus a $76 loss in Q2 2019. For the six-month period, foreign-currency losses were $48, compared with $34 in 2019.
• At June 30, cash and cash equivalents were $64.9 million, versus $3.9 million at December 31, 2019. Total assets were $67.7 million; total liabilities were $7.9 million; stockholders’ equity was $59.7 million.
• Current assets were $65.3 million and current liabilities $6.8 million. The balance sheet reports $742,000 of lease liabilities, including current and noncurrent portions; no borrowings were reported at quarter-end.
• Six-month operating cash use was $13.4 million, compared with $14.1 million in 2019. Financing provided $74.4 million, chiefly from the January private placement and June public offering. Cash increased by $61.0 million to $64.9 million.
• The company reported an accumulated deficit of $209.2 million and said it expects operating losses for the foreseeable future. Management believed June 30 cash would fund operating expenses for at least 12 months from issuance of the statements.

Material changes versus prior comparable periods

• License revenue began in 2020 under the BeiGene agreement; there was none in 2019.
• Six-month R&D expense fell $3.0 million, primarily due to lower clinical-trial costs from patient-enrollment timing and lower consulting fees. DKN-01 spending was $8.0 million versus $8.6 million; TRX518 spending fell to $2.0 million from $4.3 million.
• Six-month G&A expense rose $344,000, reflecting higher payroll and corporate, legal, audit and consulting costs, partly offset by lower stock-based compensation.
• Common shares outstanding rose from 24.2 million at December 31, 2019 to 59.7 million at June 30, 2020, following preferred-stock conversions, warrant exercises and the June offering. The filing also lists substantial outstanding warrants and options.

Outlook, risks and unusual items

• BeiGene received an option to license DKN-01 in Asia excluding Japan, Australia and New Zealand. Leap received $3.0 million upfront and may receive up to $132 million in option-exercise and milestone payments, plus tiered royalties; these future amounts are contingent, not assured.
• Management expected R&D expense to increase as DKN-01 development continues, subject to available funding. The filing provides no formal revenue, earnings or clinical-development guidance.
• COVID-19 could delay or disrupt clinical trials, enrollment, laboratory operations, manufacturing and third-party collaborators, potentially increasing development timelines and costs. The extent of impact was uncertain.
• Management cited clinical, regulatory, funding and market-acceptance uncertainty. It also noted that trial outcomes, enrollment and regulatory requirements could materially change development costs and timing.
• European patent disputes concerning TRX518 remained pending: one appeal sought broader claims, with a hearing scheduled for September 2020; a separate appeal challenged revocation of another patent.
• Six-month 2020 common-stockholder loss included $303,000 of warrant down-round dividends and $372,000 of preferred-stock dividends, plus a $9.399 million beneficial-conversion-feature charge. These accounting items increased loss attributable to common stockholders beyond reported net loss.
• The company received and repaid a $662,420 Paycheck Protection Program loan in April 2020. It reported no material changes to risk factors other than the added COVID-19 risk disclosure, and no legal proceedings under Part II, Item 1.

Important facts for investors to verify

1. Confirm the intended issuer: the supplied filing is Leap Therapeutics, Inc., not CYPHERPUNK TECHNOLOGIES INC.
2. Review the June 2020 offering, January 2020 private placement, and warrants for dilution, exercise terms and any further financing needs.
3. Assess cash burn and runway against the company’s stated 12-month estimate, recognizing continued expected operating losses and clinical-development spending.
4. Check the status and results of DKN-01 trials, COVID-19-related disruptions, and any exercise or termination of BeiGene’s option.
5. Track the TRX518 patent appeals and distinguish contingent BeiGene milestones and royalties from recognized revenue and available cash.